Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 212-974-6 | CAS number: 894-86-0
Carcinogenicity
Administrative data
Description of key information
Carcinogenic effects
Key value for chemical safety assessment
Carcinogenicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Carcinogenicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Justification for classification or non-classification
No evidence for carcinogenic properties
Additional information
Carcinogenicity: oral
There is 2 year repeated dose feeding study in rats with Indigo Blue (Weir RJ, 1967a; Ferber, 1987). Male and female F344/N rats (25 rats/sex/dose group) were orally fed dose levels of 0.25%, 1% or 3% indigo (100, 400, 1200 mg/kg/day) for 2 years; 80 control rats/sex received the plain diet only. No toxicologically relevant changes were observed during in-life or post-mortem observations. The study appeared to demonstrate that after a period of adjustment to the higher dosage levels, the rats were able to tolerate up to 3% of this substance in their diets without serious effects. NOEL for repeated dose toxicity is considered to be 1200 mg/kg/day no proliferative changes were observed at this dose level.
Carcinogenicity: inhalation
No data available.
Carcinogenicity: dermal
In a dermal lifetime study in mice, indigo was applied as a 1% solution (W/V) in spectro-grade benzene at a dose of 1 mg of test material (once/week) for up to 95 weeks, to 50 male and 50 female Swiss-Webster mice (Weir RJ, 1967c; Ferber KH, 1987). 100 males and 100 females were used as negative controls (no treatment). 100 males and 100 females received application of the vehicle (benzene). Microscopic examination of the skin (application site) was performed from all animals died or sacrificed in the first 9 months and of the liver from 9 to 13 mice/group. Microscopic examination of the lungs, liver and skin (application site) from 10 negative controls, 10 vehicle controls, and 10 compound-treated animals were performed at 75 weeks. At the terminal sacrifice (95 weeks), sections of lung, liver and skin from 29 negative controls, 26 vehicle controls and 13 compound-treated animals were examined microscopically. Histopathology was also performed on most tissues and on grossly abnormal organs of the animals. No evidence was found that in mice repeated dermal application of indigo at 1 mg/animal, once per week for up to 95 weeks produced any effect attributable to the test substance. Lesions and tumors seen in treated mice were comparable to those in vehicle control animals.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
